Literature DB >> 6369072

Mechanisms governing the relative proportions of thyroxine and 3,5,3'-triiodothyronine in thyroid secretion.

P Laurberg.   

Abstract

In subjects with normal thyroid function only a minor part of firculating 3,5,3'-triiodothyronine (T3) originates directly from the thyroid; the majority is produced in the peripheral tissues by deiodination of thyroxine (T4). However, T3 of thyroidal origin constitutes a relatively high fraction of the total T3 produced in many patients with thyroid hyperfunction or hypofunction. Such a relatively high T3 content in the secretion of the thyroid could be caused by a low T4/T3 ratio in thyroglobulin. Severe iodine deficiency is a well-known inducer of a low T4/T3 ratio, but a low T4/T3 ratio can also be produced independent of the iodine content. This is seen in in vitro studies of thyroglobulin iodination when small amounts of DIT are added to the incubation mixture and in vivo in TSH-treated animals and in patients with Graves' disease. Another mechanism for high thyroidal secretion of T3 could be an enhanced fractional deiodination of T4 to T3 in the thyroid. In vitro thyroid perfusion studies have shown that the T3 content of thyroid secretions is higher than would be expected from the T4/T3 ratio of thyroid hydrolysate and that the major mechanism is deiodination of T4 to T3. Thyroxine deiodinases are also present in the human thyroid, and the amount of T4 deiodinase is enhanced in the thyroids from patients with medically treated Graves' disease and in the hyperstimulated thyroids of rats. Other factors of possible importance for the mixture of T3 and T4 secreted by the thyroid are a relatively faster liberation of T3 than of T4 from thyroglobulin during partial hydrolysis (this faster release of T3 is probably the mechanism behind the more "rapid" secretion of T3 than of T4), or some kind of thyroid heterogeneity leading to pinocytosis and hydrolysis of thyroglobulin with a lower T4/T3 ratio than that of average thyroglobulin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6369072     DOI: 10.1016/0026-0495(84)90203-8

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  21 in total

1.  The -258A/G (SNP rs12885300) polymorphism of the human type 2 deiodinase gene is associated with a shift in the pattern of secretion of thyroid hormones following a TRH-induced acute rise in TSH.

Authors:  Maya Y Peltsverger; Peter W Butler; Anna Teresa Alberobello; Sheila Smith; Yanina Guevara; Ornella M Dubaz; Javier A Luzon; Joyce Linderman; Francesco S Celi
Journal:  Eur J Endocrinol       Date:  2012-02-03       Impact factor: 6.664

2.  When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves' disease be discontinued?

Authors:  Suyeon Park; Eyun Song; Hye-Seon Oh; Mijin Kim; Min Ji Jeon; Won Gu Kim; Tae Yong Kim; Young Kee Shong; Doo Man Kim; Won Bae Kim
Journal:  Endocrine       Date:  2019-06-24       Impact factor: 3.633

3.  Triumphs of the thyroid despite lesser conversion.

Authors:  Jessica A Hall; Antonio C Bianco
Journal:  Endocrinology       Date:  2009-06       Impact factor: 4.736

Review 4.  Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling.

Authors:  Balázs Gereben; Ann Marie Zavacki; Scott Ribich; Brian W Kim; Stephen A Huang; Warner S Simonides; Anikó Zeöld; Antonio C Bianco
Journal:  Endocr Rev       Date:  2008-09-24       Impact factor: 19.871

Review 5.  Paradigms of Dynamic Control of Thyroid Hormone Signaling.

Authors:  Antonio C Bianco; Alexandra Dumitrescu; Balázs Gereben; Miriam O Ribeiro; Tatiana L Fonseca; Gustavo W Fernandes; Barbara M L C Bocco
Journal:  Endocr Rev       Date:  2019-08-01       Impact factor: 19.871

6.  The Thr92Ala 5' type 2 deiodinase gene polymorphism is associated with a delayed triiodothyronine secretion in response to the thyrotropin-releasing hormone-stimulation test: a pharmacogenomic study.

Authors:  Peter W Butler; Sheila M Smith; Joyce D Linderman; Robert J Brychta; Anna Teresa Alberobello; Ornella M Dubaz; Javier A Luzon; Monica C Skarulis; Craig S Cochran; Robert A Wesley; Frank Pucino; Francesco Saverio Celi
Journal:  Thyroid       Date:  2010-11-07       Impact factor: 6.568

7.  Type 2 iodothyronine deiodinase is highly expressed in human thyroid.

Authors:  D Salvatore; H Tu; J W Harney; P R Larsen
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

Review 8.  Physiological role and regulation of iodothyronine deiodinases: a 2011 update.

Authors:  A Marsili; A M Zavacki; J W Harney; P R Larsen
Journal:  J Endocrinol Invest       Date:  2011-03-21       Impact factor: 4.256

Review 9.  Individualized Therapy for Hypothyroidism: Is T4 Enough for Everyone?

Authors:  Matthew D Ettleson; Antonio C Bianco
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

10.  Dual mechanisms of regulation of type I iodothyronine 5'-deiodinase in the rat kidney, liver, and thyroid gland. Implications for the treatment of hyperthyroidism with radiographic contrast agents.

Authors:  D L St Germain
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.